JP6295205B2 - 心血管疾患のリスクを低減する方法 - Google Patents

心血管疾患のリスクを低減する方法 Download PDF

Info

Publication number
JP6295205B2
JP6295205B2 JP2014551345A JP2014551345A JP6295205B2 JP 6295205 B2 JP6295205 B2 JP 6295205B2 JP 2014551345 A JP2014551345 A JP 2014551345A JP 2014551345 A JP2014551345 A JP 2014551345A JP 6295205 B2 JP6295205 B2 JP 6295205B2
Authority
JP
Japan
Prior art keywords
patient
ldl
compound
pharmaceutical composition
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503588A (ja
JP2015503588A5 (cg-RX-API-DMAC7.html
Inventor
チャールズ エル． ビズゲイール
チャールズ エル． ビズゲイール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metavia
Original Assignee
Gemphire Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics LLC filed Critical Gemphire Therapeutics LLC
Publication of JP2015503588A publication Critical patent/JP2015503588A/ja
Publication of JP2015503588A5 publication Critical patent/JP2015503588A5/ja
Application granted granted Critical
Publication of JP6295205B2 publication Critical patent/JP6295205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014551345A 2012-01-06 2013-01-04 心血管疾患のリスクを低減する方法 Active JP6295205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
US61/584,002 2012-01-06
PCT/US2013/020317 WO2013103842A1 (en) 2012-01-06 2013-01-04 Methods of reducing risk of cardiovascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018026939A Division JP2018104452A (ja) 2012-01-06 2018-02-19 心血管疾患のリスクを低減する方法

Publications (3)

Publication Number Publication Date
JP2015503588A JP2015503588A (ja) 2015-02-02
JP2015503588A5 JP2015503588A5 (cg-RX-API-DMAC7.html) 2016-02-18
JP6295205B2 true JP6295205B2 (ja) 2018-03-14

Family

ID=48745439

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014551345A Active JP6295205B2 (ja) 2012-01-06 2013-01-04 心血管疾患のリスクを低減する方法
JP2018026939A Pending JP2018104452A (ja) 2012-01-06 2018-02-19 心血管疾患のリスクを低減する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018026939A Pending JP2018104452A (ja) 2012-01-06 2018-02-19 心血管疾患のリスクを低減する方法

Country Status (9)

Country Link
US (2) US10028926B2 (cg-RX-API-DMAC7.html)
EP (2) EP3735967A1 (cg-RX-API-DMAC7.html)
JP (2) JP6295205B2 (cg-RX-API-DMAC7.html)
CN (2) CN110025608A (cg-RX-API-DMAC7.html)
AU (1) AU2013207423B2 (cg-RX-API-DMAC7.html)
CA (1) CA2861643C (cg-RX-API-DMAC7.html)
HK (1) HK1201452A1 (cg-RX-API-DMAC7.html)
MX (1) MX367352B (cg-RX-API-DMAC7.html)
WO (1) WO2013103842A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2016077832A2 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
SG10201912754UA (en) * 2015-11-06 2020-02-27 Gemphire Therapeutics Inc Treatment of mixed dyslipidemia
MX2018010096A (es) * 2016-02-26 2018-11-09 Gemphire Therapeutics Inc Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.
EP4461295A3 (en) * 2017-02-08 2025-01-15 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
CA3059073A1 (en) * 2017-04-18 2018-10-25 Daniela Carmen Oniciu Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
TW201906599A (zh) * 2017-05-11 2019-02-16 美商珍費爾醫療公司 吉卡賓組成物及其使用方法
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
MX2021015935A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Formas de sal de acido bempedoico y metodos para utilizar el mismo.
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
DE60037818D1 (de) 1999-04-01 2008-03-06 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
JP2004529069A (ja) 2000-10-11 2004-09-24 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
JP5270545B2 (ja) 2006-08-03 2013-08-21 タフツ ユニバーシティー／トラスティーズ オブ タフツ カレッジ フラッシングのないナイアシン類似体およびそれらの使用法

Also Published As

Publication number Publication date
US20150005386A1 (en) 2015-01-01
AU2013207423A1 (en) 2014-07-24
US20180303779A1 (en) 2018-10-25
JP2015503588A (ja) 2015-02-02
EP2800564B1 (en) 2020-05-06
CA2861643A1 (en) 2013-07-11
AU2013207423B2 (en) 2017-10-12
US10709678B2 (en) 2020-07-14
CA2861643C (en) 2020-10-06
EP2800564A1 (en) 2014-11-12
CN104136023A (zh) 2014-11-05
MX367352B (es) 2019-08-16
CN110025608A (zh) 2019-07-19
US10028926B2 (en) 2018-07-24
WO2013103842A1 (en) 2013-07-11
JP2018104452A (ja) 2018-07-05
EP2800564A4 (en) 2015-07-22
HK1201452A1 (en) 2015-09-04
EP3735967A1 (en) 2020-11-11
MX2014008180A (es) 2014-10-14

Similar Documents

Publication Publication Date Title
JP6295205B2 (ja) 心血管疾患のリスクを低減する方法
Nikolic et al. ETC-1002: a future option for lipid disorders?
WO2013136277A1 (en) Pharmaceutical compositions for treatment of cardiovascular diseases
JP6940411B2 (ja) Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
CN114159564A (zh) 包含etc1002及他汀类药物的固定剂量组合
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
Atar et al. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Tardif et al. High-density lipoprotein/apolipoprotein AI infusion therapy
JP6207560B2 (ja) 膵炎を治療するためのゲムカベンおよび誘導体
HK40007806A (en) Methods of reducing risk of cardiovascular disease
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
Hamilton-Craig Managing residual risk in patients receiving statin therapy
Genest 75 Secondary prevention strategies post myocardial infarction
Pitsavos Beyond LDL Cholesterol: The role of LDL particles and HDL
Patel et al. Lipid-Modifying Therapy
Davidson 505 COMBINATION THERAPY WITH STATINS AND OMEGA 3 FATTY ACIDS
Ganda Lipid management in the metabolic syndrome

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20150327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180219

R150 Certificate of patent or registration of utility model

Ref document number: 6295205

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250